Drug intelligence / Profile preview

soluble Peptide X

Development stage
Preclinical
Lead developer
Asahikawa Medical University
Modality
Peptides
Administration
Parenteral
01

Overview

Soluble Peptide X (also known as soluble Ninjurin-1 or sNinj1) is the soluble, cleaved extracellular domain of Ninjurin-1 (Ninj1), an adhesion molecule originally identified for its role in peripheral nerve regeneration. Ninjurin-1 is cleaved by matrix metalloproteinase-9 (MMP-9) to release sNinj1, which acts as an anti-inflammatory and atheroprotective agent. Soluble Peptide X (sNinj1) and its mimetic peptides (such as ML56 and PN12) function by binding to membrane-bound Ninjurin-1, thereby inhibiting homophilic Ninjurin-1 interactions, suppressing macrophage activation, and reducing monocyte transendothelial migration. In preclinical models, sustained-release formulations of sNinj1 (such as PLGA microspheres/nanoparticles) have demonstrated therapeutic potential in attenuating post-infarction adverse cardiac remodeling and reducing atherosclerosis by suppressing inflammatory cell infiltration and myocardial fibrosis.

Other names
ML56ML-56ML 56PN12PN-12PN 12sNinj1sNinj-1sNinj 1sPeptide Xsoluble Ninj1soluble Ninjurin-1
02

Targets

NINJ1 (Ninjurin-1)

Beyond the preview

Go deeper on soluble Peptide X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on soluble Peptide X.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call